Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

Nitesh sinha December 20, 2023
https://ift.tt/os9kIx3

Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint



from Sanofi - Aventis Groupe https://ift.tt/XGJmAoH
via IFTTT
Tags:
Nitesh sinha

Posted by: Nitesh sinha

Post a Comment

0 Comments

Please ,
Do not enter any kind of span link